

10/574744

CASE 33397-US-PCT

IAP15 Rec'd PCT/PTO 06 APR 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

PAUL E. GOSS

INTERNATIONAL APPLICATION NO: PCT/EP2004/011303

FILED: 8 OCTOBER 2004

U.S. APPLICATION NO:

35 USC §371 DATE:

FOR: BREAST CANCER TREATMENT REGIMEN

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/011303, copies are not enclosed herewith.

10/574744

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

JAP15 Rec'd PCT/PTO 06 APR 2006

Respectfully submitted,



Lydia T. McNally
Attorney for Applicant
Reg. No. 36,214

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898

Date: April 6, 2006

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Goss et al., "A Randomised Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer," New England Journal of Medicine, Vol. 349, No. 19, pp. 1793-1802 (2003)
	AS	Goss, "Breast cancer prevention - clinical trials strategies involving aromatase inhibitors," Journal of Steroid Biochemistry and Molecular Biology, Vol. 86, pp. 487-493 (2003)
	AT	Goss et al., "Tamoxifen Resistant and Refractory Breast Cancer," Drugs, Vol. 62, No. 2, pp. 957-966 (2002)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

IAP15 Rec'd PCT/PTO 06 APR 2006
Sheet 2 of 2
10/574744

ATTY. DOCKET NO.
33397-US-PCT
APPLICATION NO.
Not Yet Known
APPLICANT
Paul E. GOSS
FILING DATE
Herewith

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Jones, "Antiaromatase Agents: Evolving Role in Adjuvant Therapy," Clinical Breast Cancer, Vol. 3, No. 1, pp. 33-42 (2002)
	DB	Goss, "The Evolving Role of Aromatase Inhibitors in the Adjuvant Breast Cancer Setting," American Journal of Cancer, Vol. 2, No. 1, pp. 13-15 (2003)
	DC	Ingle et al., "Evaluation of Tamoxifen plus Letrozole with Assessment of Pharmacokinetic Interaction in Postmenopausal Women with Metastatic Breast Cancer," Clinical Cancer Research, Vol. 5, pp. 1642-1649 (1999)
	DD	Goss, "Preliminary Data from Ongoing Adjuvant Aromatase Inhibitor Trials," Clinical Cancer Research, Vol. 7, pp. 4397S-4401S (2001)
	DE	Hill et al., "Aromatase inhibitors in breast cancer: Current and evolving roles," Current Drug Therapy, Vol. 69, No. 7 pp. 561-567 (2002)
	DF	Goss, "Anti-Aromatase Agents in the Treatment and Prevention of Breast Cancer" Cancer Control, H. Lee Moffitt Cancer Center and Research Institute, Vol. 9, No. 2 (Suppl.), pp. 2-8 (2002)
	DG	Goss et al., "Letrozole for the management of breast cancer," Expert Review of Anticancer therapy, "Vol. 2, No. 3, pp. 249-260 (2002)
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.